Last reviewed · How we verify

Brimonidine Tartrate Gel

LEO Pharma · Phase 2 active Small molecule

Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin.

Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin. Used for Treatment of erythema associated with rosacea.

At a glance

Generic nameBrimonidine Tartrate Gel
SponsorLEO Pharma
Drug classAlpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

Brimonidine tartrate gel is an alpha-2 adrenergic agonist that decreases the production of norepinephrine, a neurotransmitter that can cause blood vessels to dilate and increase blood flow to the skin. By reducing norepinephrine levels, brimonidine tartrate gel helps to decrease redness and swelling in the skin, making it a useful treatment for conditions such as rosacea.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: